Clozapine

CHEMBL42 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

326.8 g/mol

LogP

3.1

Phase

4

An atypical antipsychotic reserved for treatment-resistant schizophrenia due to its risk of potentially fatal agranulocytosis, requiring regular blood monitoring. It acts on multiple neurotransmitter receptors and is highly effective in patients who have not responded to other antipsychotics.

الوزن الجزيئي

326,8000 g/mol

LogP

3,10

TPSA

30,90 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Pain Management Alzheimer's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Gastroesophageal Reflux Disease Chronic Kidney Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Chronic Pain Heart Failure Leukemia

آلية العمل

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1

InChI

InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

Molecular Formula

C18H19ClN4

HBD / HBA

1 / 3

الروابط القابلة للدوران

1

الذرات الثقيلة

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An atypical antipsychotic reserved for treatment-resistant schizophrenia due to its risk of potentially fatal agranulocytosis, requiring regular blood monitoring. It acts on multiple neurotransmitter receptors and is highly effective in patients who have not responded to other antipsychotics.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Clozapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL42. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135398737. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Clozapine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C18H19ClN4
المرادفات: 2

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.